DDInter927 DDInter1561
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin. Xofigo is indicated in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant. The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm.
Radium Ra 223 dichloride {u} (Compound) causes {v} (Side Effect) Extravasation
Radium Ra 223 dichloride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lomustine
Radium Ra 223 dichloride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sarilumab
Radium Ra 223 dichloride {u} may lead to a major life threatening interaction when taken with {v} Abiraterone
Radium Ra 223 dichloride (Compound) causes Extravasation (Side Effect)
Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Lomustine
Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Radium Ra 223 dichloride may lead to a major life threatening interaction when taken with Abiraterone